APA (7th ed.) Citation

Hosseini, I., Fleisher, B., Getz, J., Decalf, J., Kwong, M., Ovacik, M., . . . Ramanujan, S. (2024). A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics, 16(5), 660. https://doi.org/10.3390/pharmaceutics16050660

Chicago Style (17th ed.) Citation

Hosseini, Iraj, et al. "A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule." Pharmaceutics 16, no. 5 (2024): 660. https://doi.org/10.3390/pharmaceutics16050660.

MLA (9th ed.) Citation

Hosseini, Iraj, et al. "A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule." Pharmaceutics, vol. 16, no. 5, 2024, p. 660, https://doi.org/10.3390/pharmaceutics16050660.